Regulatory watch

HHS draft policy on six compounded peptides. On October 28, 2026, the U.S. Department of Health and Human Services posted a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It describes when HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy applies while FDA builds the formal 503A bulks list through rulemaking. The Federal Register notice (docket HHS-OASH-2026-0496) opened a two-week public comment period.

What it does not mean. Enforcement discretion is not FDA approval. None of these six peptides has been shown to be safe and effective in adequately powered human trials. The draft is not binding and can be revised or withdrawn. It covers patient-specific compounding by licensed pharmacies that meet the policy conditions, not "research use only" products sold online. Legal analyses also note that combination products, such as BPC-157 and TB-500 mixed in one vial, fall outside the policy as written.

How we got here. In 2023 FDA placed many popular peptides in Category 2, its list of bulk substances that may raise significant safety concerns. In April 2026 FDA removed 12 peptides, including BPC-157, from Category 2 after their nominations were withdrawn, without moving them to the list that permits compounding. In July 2026 FDA's Pharmacy Compounding Advisory Committee reviewed several of them. This draft policy is the first federal action to follow those votes.

Sources: Federal Register notice · BakerHostetler summary · FDA Law Blog analysis

Research roundup

BPC-157 in people: three small studies, very low certainty [Systematic review · Human studies]

A PRISMA-registered review searched four databases through June 2026 for any human study of BPC-157. Only three met the criteria, with 30 participants in total: a retrospective study of knee injections (16 people), a retrospective pilot in interstitial cystitis (12) and a two-person intravenous safety pilot. Most participants reported symptom improvement without treatment-related adverse events, but all three studies were judged poor quality and the overall certainty was rated very low.

What this means: The authors conclude BPC-157 should not be used clinically outside ethically approved, regulated trials. Policy access is moving faster than the human evidence.

Poolton et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine. Acta Orthop Belg, 2026. View on PubMed

BPC-157 in animal reperfusion injury: promising but heterogeneous [Critical review · Animal studies]

This review pooled rodent studies of ischemia-reperfusion injury, the damage that can follow restored blood flow. BPC-157 was associated with less oxidative injury, changes in nitric oxide-related vascular responses and lower inflammatory and apoptotic markers across several organ models. The authors flag short observation periods, single-dose designs and incompletely reported risk of bias.

What this means: These are rat and mouse results. The review calls BPC-157 a hypothesis-generating candidate that still needs blinded replication, toxicology and controlled human studies.

Demirtaş et al. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci, 2026. View on PubMed

Epitalon: biologically active, clinically unproven [Narrative review]

Synthetic Epitalon has been reported to influence telomere-maintenance pathways, circadian and neuroendocrine function and oxidative stress markers in preclinical work. Human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa. No adequately powered randomized trial has established benefit, and pharmacokinetic, dose-ranging and long-term safety data remain inadequate.

What this means: Epitalon is now on the HHS compounding list, yet the evidence base remains early. Any use should be framed as experimental.

Jain et al. Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence. Int J Mol Sci, 2026. View on PubMed

CagriSema vs semaglutide alone: more weight loss, more injection-site reactions [Meta-analysis · 5 randomized trials · 4,746 participants]

Compared with semaglutide 2.4 mg, the cagrilintide plus semaglutide combination produced 6.89 percentage points more weight loss (95% CI -8.70 to -5.06) and roughly doubled the chance of losing 20% of body weight (RR 2.10). Waist circumference fell a further 4.07 cm. No extra benefit on HbA1c was detected. Injection-site reactions were about three times more common, while gastrointestinal events were not significantly increased.

What this means: Amylin plus GLP-1 combinations are the next wave in metabolic peptides. Durability, cardiovascular outcomes and body composition effects are still unknown.

Rasool et al. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management. Front Endocrinol, 2026. View on PubMed

GLP-1 drugs and fatty liver disease [Meta-analysis · 9 studies · 795 participants]

In adults with MASLD or MASH, GLP-1 receptor agonists were associated with lower liver fat content (mean difference -3.17), lower ALT (-15.17) and AST (-9.89), weight loss of 4.68 and an HbA1c reduction of 0.78. Nausea and vomiting were more common, while serious adverse events did not differ.

What this means: Liver fat and enzymes improve, but the authors note that longer trials are needed to show effects on fibrosis and liver-related outcomes.

Alfawaz et al. Efficacy and safety of GLP-1 receptor agonists in MASLD and MASH. Medicine (Baltimore), 2026. View on PubMed

GLP-1 drugs and obstructive sleep apnea [Meta-analysis · 6 randomized trials · 1,069 participants]

Across liraglutide and tirzepatide trials in moderate to severe sleep apnea, treatment reduced the apnea-hypopnea index by about 10 events per hour and body weight by about 9.7 kg, with modest blood pressure reductions. Oxygen desaturation measures did not differ, and heterogeneity between trials was high.

What this means: Tirzepatide is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity. The authors stress these drugs support, but do not replace, CPAP.

Carvalhal et al. GLP-1 receptor agonists for obstructive sleep apnea: a meta-analysis of randomized controlled trials. Sleep Breath, 2026. View on PubMed

Elamipretide and egg quality in reproductive aging [Animal and laboratory study]

In aged mice, elamipretide increased litter size and improved several markers of egg (oocyte) quality. In the laboratory it also improved maturation, fertilization and early cleavage of aged human eggs, which the authors link to the vitamin B6 and VEGF pathway.

What this means: Elamipretide is FDA-approved only for Barth syndrome. These fertility findings come from animals and lab dishes and have not been tested in women.

Zhang et al. Elamipretide Rejuvenates Oocyte Quality and Restores Female Fertility During Reproductive Aging. Aging Cell, 2026. View on PubMed

MOTS-c and the cells that support aging eggs [Laboratory and animal study]

In an aging-associated human granulosa cell model and in eggs from aged mice, MOTS-c increased mitochondrial respiration and markers of antioxidant defense and improved some egg maturation outcomes, although results stayed below those of young controls.

What this means: Interesting biology for a peptide now on the HHS compounding list, but the authors state the findings are from lab and animal experiments, not women.

Tsui et al. The mitochondrial-derived peptide MOTS-c improves bioenergetics in aging-associated granulosa cells and oocytes. Reprod Fertil, 2026. View on PubMed

Safety and quality watch

The risks of unregulated "biohacking" injectables. A 2026 review in Missouri Medicine describes the growing online market for injectable peptides used without a prescription, including BPC-157, TB-500, melanotan-II and the investigational drug retatrutide. It highlights contamination, manufacturing impurities, inaccurate dosing and unknown long-term effects. View on PubMed

Our take: products labeled "research use only" are not made for people and are not covered by the HHS policy. If you are considering any peptide, talk with a licensed clinician and use only a licensed pharmacy.

What this means for you

For patients: Access is changing faster than the science. A peptide being compoundable does not mean it is proven, and most of the human data are still small or early. Bring questions, and this Brief, to your own clinician.

For clinicians: Read the HHS conditions closely before changing practice, including sourcing, testing and adverse event reporting. Document informed consent that names the evidence level and regulatory status. Report adverse events.

On our radar

• The final version of the HHS peptide policy after the comment period closes.

• FDA rulemaking on the formal 503A bulks list.

• Phase 3 readouts for retatrutide and other next-generation incretin peptides.

• The first registered controlled human trials of BPC-157.